Psilocybin-assisted therapy could help patients with cancer and major depression disorder, according to new data from an open-label Phase II trial published in JAMA Oncology.

Sunstone Therapies reported results from a 30-patient Phase II trial suggesting psilocybin and group therapy could lead to sustained reductions of depression symptoms in patients with cancer. The study’s authors noted that the trial lacked a placebo arm, but said the promising results justified a subsequent randomized control trial.

Rockville, Maryland-based Sunstone ran the study out of a community cancer center in Maryland. Patients received a 25mg dose of synthesized psilocybin alongside group and individual therapy, using a 1:1 patient to therapist ratio.

Psilocybin, which is the main psychoactive ingredient found in psychedelic ‘magic mushrooms,’ has been linked to improvement in several mental health conditions during early clinical research. Shifting clinical regulatory perspectives have led to a recent surge in clinical trials testing psychedelics, though most data is from early-stage clinical trials.

Positive Phase II data

In the Phase II study, psilocybin treatment led to a statistically significant, 19.1-point reduction in Montgomery-Asberg Depression Rating Scale (MADRS), measured eight weeks after treatment. MADRS is a ten-item questionnaire that psychiatrists use to measure symptoms of depression, leading to a final score between 0–60. Scores of 35–60 represent severe depression, 20–34 moderate depression, 7–19 mild depression, and 0–6 no depression.

The trial also led to a sustained response of symptom reduction in 80% of patients, with 15 of the 30 patients experiencing full remission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

No patients reported treatment-related serious adverse events, though the majority experienced mild adverse events. These included headache in 24 patients, nausea in 12 patients, and altered mood in eight patients.

Fourteen trial patients had curable cancers, and 16 patients had incurable cancers. Half of the enrolled patients reported previous treatment with an antidepressant drug therapy.